Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer

25 Jul 2024

Abstract excerpt

The clinical outcomes in patients with ovarian cancer have been significantly improved by Poly(adenosine diphosphate–ribose) polymerase inhibitors (PARP-is). However, the best therapeutic strategy for recurrence during PARP-i maintenance therapy remains unknown. Herein, we elucidated the efficacy of platinum-based chemotherapy after PARP-i treatment in recurrent ovarian cancer. Eligible patients had experienced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39123379
DOI: 10.3390/cancers16152651

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian CancerPMID 39123379Read ↗

Efficacy and Safety of Bevacizumab-Combined Single-Agent Chemotherapy for Platinum-Resistant Ovarian Cancer that Recurred During PARP Inhibitor TreatmentSemantic proximity Read ↗

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity Read ↗

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysisSemantic proximity Read ↗

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapySemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read ↗

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian CancerSemantic proximity Read ↗

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.Semantic proximity Read ↗

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

The effect of PARPi maintenance therapy on re-chemotherapy in advanced ovarian cancerSemantic proximity Read ↗

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.Semantic proximity Read ↗

The Changes in BRCA Mutation Status and Their Impact on Recurrence in Ovarian Cancer Patients After Oral PARPi TreatmentSemantic proximity Read ↗

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.